IMRX Stock Overview A clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Immuneering Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Immuneering Historical stock prices Current Share Price US$1.94 52 Week High US$7.68 52 Week Low US$1.00 Beta -0.34 1 Month Change -17.09% 3 Month Change 4.30% 1 Year Change -65.66% 3 Year Change -80.20% 5 Year Change n/a Change since IPO -88.97%
Recent News & Updates
Immuneering Corporation Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer Jan 15
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms Jan 07
Immuneering Launches Pancreatic Cancer Advisory Board Dec 20
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma Dec 13
Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients Sep 13
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky Aug 30 See more updates
Immuneering Corporation Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer Jan 15
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms Jan 07
Immuneering Launches Pancreatic Cancer Advisory Board Dec 20
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma Dec 13
Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients Sep 13
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky Aug 30 Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans? May 13
Immuneering Corporation, Annual General Meeting, Jun 12, 2024 Apr 24
Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting Apr 10
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations Mar 27
Independent Chair recently bought US$123k worth of stock Mar 20
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone Mar 19
Price target decreased by 12% to US$16.86 Mar 16
Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors Mar 15
New major risk - Share price stability Mar 15
Less than half of directors are independent Mar 15
Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors Mar 12
Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors Mar 11
New major risk - Revenue and earnings growth Mar 05
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer Feb 21
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans? Jan 06
New major risk - Share price stability Dec 02
Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022) Nov 10
New minor risk - Share price stability Oct 31
Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference Oct 13
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate Aug 17
First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022) Aug 04
Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023 Jun 16
New major risk - Revenue and earnings growth Jun 09
First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022) May 06
Price target decreased by 12% to US$18.71 Mar 31
Consensus revenue estimates decrease by 80%, EPS upgraded Mar 13
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 07
Price target decreased to US$21.33 Jan 05
Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations Nov 29
Consensus revenue estimates fall by 26% Nov 17
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Nov 16
Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer Oct 21
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Oct 06
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations Oct 01
Immuneering wins FDA nod to study lead asset in solid tumors Sep 30
Immuneering Corporation Announces Committee Changes Sep 20
Consensus forecasts updated Sep 14
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations Sep 03
Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate Sep 02
Consensus forecasts updated Aug 17
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11 Immuneering Corporation Announces Management Changes
Immuneering initiated a Buy by Chardan, PT set to $18 Jul 08 Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104 May 27
Consensus forecasts updated May 17
First quarter 2022 earnings: EPS misses analyst expectations May 10
Immuneering Corporation, Annual General Meeting, Jun 21, 2022 May 03
Consensus revenue estimates fall by 75% Mar 17
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 11
Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model Jan 07
Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million. Dec 23
Third quarter 2021 earnings released: US$0.47 loss per share Nov 12
Director recently bought US$116k worth of stock Sep 23
Director recently bought US$131k worth of stock Sep 17
Less than half of directors are independent Jul 31 Shareholder Returns IMRX US Biotechs US Market 7D -5.8% 1.8% -0.8% 1Y -65.7% -2.1% 22.7%
See full shareholder returns
Return vs Industry: IMRX underperformed the US Biotechs industry which returned -2.1% over the past year.
Return vs Market: IMRX underperformed the US Market which returned 22.7% over the past year.
Price Volatility Is IMRX's price volatile compared to industry and market? IMRX volatility IMRX Average Weekly Movement 13.0% Biotechs Industry Average Movement 11.2% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stable Share Price: IMRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IMRX's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Show more Immuneering Corporation Fundamentals Summary How do Immuneering's earnings and revenue compare to its market cap? IMRX fundamental statistics Market cap US$60.24m Earnings (TTM ) -US$58.07m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMRX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$58.07m Earnings -US$58.07m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 13:01 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Immuneering Corporation is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yevgeniya Livshits Chardan Capital Markets, LLC Michael Schmidt Guggenheim Securities, LLC Michael Yee Jefferies LLC
Show 9 more analysts 
